The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
Open accessAbstract
Here we describe the generation of an antibody–drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker. By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia patients, suggesting that anti–CD79b-vcMMAE could be widely used in these malignancies. By using NHL cell lines to simulate a patient population we discovered that a minimal cell-surface expression level of CD79b was required for in vitro activity. Within the subpopulation of cell lines above this minimal threshold, we found that sensitivity to free MMAE, mutation of cancer genes, and cell doubling time were poorly correlated with in vitro activity; however, the expression level of BCL-XL was correlated with reduced sensitivity to anti–CD79b-vcMMAE. This observation was supported by in vivo data showing that a Bcl-2 family inhibitor, ABT-263, strikingly enhanced the activity of anti–CD79b-vcMMAE. Furthermore, anti–CD79b-vcMMAE was significantly more effective than a standard-of-care regimen, R-CHOP (ie, rituximab with a single intravenous injection of 30 mg/kg cyclophosphamide, 2.475 mg/kg doxorubicin, 0.375 mg/kg vincristine, and oral dosing of 0.15 mg/kg prednisone once a day for 5 days), in 3 xenograft models of NHL. Together, these data suggest that anti–CD79b-vcMMAE could be broadly efficacious for the treatment of NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Antibody framework residues affecting the conformation of the hypervariable loops
Foote, J., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)91010-m · Cited by 524
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Zenz, T., Kröber, A., Scherer, K., Häbe, S., Bühler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwänen, C., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154070 · Cited by 386
Bcl-2 and Bcl-XL Can Differentially Block Chemotherapy-Induced Cell Death
Simonian, P. L., Grillot, D. A. M., & Nuñez, G. (1997) · Blood · doi:10.1182/blood.v90.3.1208 · Cited by 242
Cited by
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115304 · Cited by 926
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Metadata
- Authors
- Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., Koeppen, H., Lau, J., McBride, J., Rawstron, A., Shi, X., Yu, N., Yu, S.-F., Yue, P., Zheng, B., Ebens, A., & Polson, A. G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-09-24
- Volume
- 114
- Issue
- 13
- Pages
- 2721-2729
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2089197481
- Cited by
- 273
- References
- 21
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2009-02-205500
- The paper
- Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., Koeppen, H., Lau, J., McBride, J., Rawstron, A., Shi, X., Yu, N., Yu, S.-F., Yue, P., Zheng, B., . . . Polson, A. G. (2009). Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2009-02-205500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.